Fulcrum Therapeutics (FULC) Operating Income (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Operating Income of -$22.2 million for Q1 2026, down 8.74% year-over-year from -$24.3 million in Q1 2025, and up 2.23% quarter-over-quarter from -$22.7 million in Q4 2025.
Fulcrum Therapeutics (FULC) Operating Income (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Operating Income data on file, last reported at -$22.2 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$22.2 million, down 8.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.6 million (down 594.3% YoY), and the FY2025 annual result was -$84.8 million, down 287.13% from the prior year.
- Operating Income advanced to -$22.2 million in Q1 2026 per FULC's latest filing, from -$22.7 million in the prior quarter.
- Over five years, Operating Income peaked at $52.5 million in Q2 2024 and troughed at -$34.2 million in Q2 2022.
- A 5-year average of -$20.7 million and a median of -$25.1 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income jumped 292.33% in 2024, then tumbled 137.75% in 2025.
- A 5-year view of Operating Income shows it stood at -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then soared by 30.59% to -$19.4 million in 2024, then fell by 16.8% to -$22.7 million in 2025, then rose by 2.23% to -$22.2 million in 2026.
- Business Quant data shows FULC's Operating Income at -$22.2 million in Q1 2026, -$22.7 million in Q4 2025, and -$21.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -65.83 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -22.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -22.69 Mn |
| Sep 30, 2025 | -21.86 Mn |
| Jun 30, 2025 | -19.82 Mn |
| Mar 31, 2025 | -20.40 Mn |
| Dec 31, 2024 | -19.43 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 52.49 Mn |
| Mar 31, 2024 | -29.83 Mn |
| Dec 31, 2023 | -27.99 Mn |
| Sep 30, 2023 | -27.44 Mn |
| Jun 30, 2023 | -27.29 Mn |
| Mar 31, 2023 | -27.94 Mn |
| Dec 31, 2022 | -27.97 Mn |
| Sep 30, 2022 | -24.36 Mn |
| Jun 30, 2022 | -34.24 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -23.56 Mn |
| Sep 30, 2021 | -20.77 Mn |
| Jun 30, 2021 | -19.68 Mn |